DP2-T
DP2-T
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. These products are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease. Purchasers must be 21 years or older. By purchasing, the buyer agrees to use these products in compliance with all applicable laws and regulations.
DP2-T Overview
DP2-T is a synthetic peptide that functions as a dual-pathway (dual receptor) agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor pathways. This combination of pathway activity is under investigation in preclinical laboratory models for its ability to modulate downstream signaling cascades and molecular interactions. Research efforts focus on its role in receptor-mediated molecular responses across biological systems.
History
The concept of DP2-T stems from peptide signaling research and the discovery of key incretin regulatory pathways. After early agonist studies demonstrated the utility of targeting endocrine biology, researchers expanded into dual-agonist strategies. DP2-T was developed as an investigational compound with balanced activity at two pathway targets, designed to explore synergistic signaling in endocrine and molecular research.
DP2-T Structure
Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight: 4813.5 g/mol
PubChem ID: 137346133
Research Findings
DP2-T has been studied in structural, endocrine, and molecular models, with research highlighting its effects on downstream signaling cascades, pathway modulation, and receptor-mediated activity. Findings also emphasize its role in target pathway dynamics, intracellular signaling, and synergistic pathway interactions in preclinical settings.
Key Areas of Research:
- Dual target pathway interaction
- Endocrine: Signaling dynamics, downstream cascades
- Molecular: Target subtypes, pathway activity
- Systemic: Crosstalk, intracellular signaling
Together, these findings suggest broad experimental potential for DP2-T across structural, endocrine, and molecular systems. By modulating downstream cascades and engaging multiple pathway targets, DP2-T provides a versatile research platform for exploring signaling kinetics, pathway characterization, and integrated endocrine biology.
References
Coskun, T., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14.
Frías, J.P., et al. (2021). A dual GIP and GLP-1 receptor agonist versus a selective GLP-1 receptor agonist once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.